NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company focused on natural killer cell therapies for oncology and neurological diseases. The company entered the public markets in 2022 through a business combination with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Industrial Corp. that completed its initial public offering in 2021. Graf Acquisition Corp. IV targeted opportunities in the healthcare and life sciences sector. NKGen Biotech filed a Form 10-Q with the SEC on November 14, 2022, reflecting its status as a newly public operating company advancing its proprietary NK cell platform. Investors and analysts seeking comprehensive SPAC deal data, sponsor profiles, and filing history for NKGN can sign up for full access at SpacDesk.